Live Markets, Charts & Financial News

CSL Limited stock falls after Phase 3 setback (OTCMKTS:CSLLY)

0 27

cagkansayin

Australian biotech CSL Limited (OTCQX:CSLLY) fell ~4% on Monday, marking its biggest intraday loss in more than four months after its Phase 3 AEGIS-II trial, one of its key clinical programs, failed.

The global trial was designed to evaluate serum

Leave A Reply

Your email address will not be published.